Polypeptide-GalNAc-Transferase-13 Shows Prognostic Impact in Breast Cancer

Breast cancer is a public health concern and is currently the fifth cause of mortality worldwide. Identification of different biological subtypes is essential for clinical management; therefore, the role of pathologists is essential and useful tools for immunohistochemistry diagnosis are needed. Pol...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eugenia Fernandez, Luis Ubillos, Nabila Elgul, María Florencia Festari, Daniel Mazal, Otto Pritsch, Isabel Alonso, Eduardo Osinaga, Nora Berois
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	breast cancer GalNAc-T13 monoclonal antibody immunohistochemistry prognosis <i>O</i>-glycosylation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/330d301d32ec460dad1dd19e0b6ffb40
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:330d301d32ec460dad1dd19e0b6ffb40
record_format	dspace
spelling	oai:doaj.org-article:330d301d32ec460dad1dd19e0b6ffb402021-11-25T17:01:39ZPolypeptide-GalNAc-Transferase-13 Shows Prognostic Impact in Breast Cancer10.3390/cancers132256162072-6694https://doaj.org/article/330d301d32ec460dad1dd19e0b6ffb402021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5616https://doaj.org/toc/2072-6694Breast cancer is a public health concern and is currently the fifth cause of mortality worldwide. Identification of different biological subtypes is essential for clinical management; therefore, the role of pathologists is essential and useful tools for immunohistochemistry diagnosis are needed. Polypeptide-GalNAc-transferases are emerging novel biomarkers related to cancer behavior and GalNAc-T13, correlated with aggressiveness in some tumors, is an interesting candidate. Few monoclonal antibodies reacting with native proteins, and not affected by fixation and paraffin embedding, have been reported. The aim of this work was to develop a useful monoclonal antibody anti-GalNAc-T13 and to assess its potential significance in breast cancer diagnosis. We evaluated 6 human breast cancer cell lines, 338 primary breast tumors and 48 metastatic lymph nodes and looked for clinical significance correlating GalNAc-T13 expression with patients’ clinical features and survival. We found high GalNAc-T13 expression in 43.8% of the cases and observed a significant higher expression in metastatic lymph nodes, correlating with worse overall survival. We hypothesized several possible molecular mechanisms and their implications. We conclude that GalNAc-T13 may be a novel biomarker in breast cancer, useful for routine pathological diagnosis. Elucidation of molecular mechanisms related to aggressiveness should contribute to understand the role of GalNAc-T13 in breast cancer biology.Eugenia FernandezLuis UbillosNabila ElgulMaría Florencia FestariDaniel MazalOtto PritschIsabel AlonsoEduardo OsinagaNora BeroisMDPI AGarticlebreast cancerGalNAc-T13monoclonal antibodyimmunohistochemistryprognosis<i>O</i>-glycosylationNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5616, p 5616 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer GalNAc-T13 monoclonal antibody immunohistochemistry prognosis <i>O</i>-glycosylation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	breast cancer GalNAc-T13 monoclonal antibody immunohistochemistry prognosis <i>O</i>-glycosylation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Eugenia Fernandez Luis Ubillos Nabila Elgul María Florencia Festari Daniel Mazal Otto Pritsch Isabel Alonso Eduardo Osinaga Nora Berois Polypeptide-GalNAc-Transferase-13 Shows Prognostic Impact in Breast Cancer
description	Breast cancer is a public health concern and is currently the fifth cause of mortality worldwide. Identification of different biological subtypes is essential for clinical management; therefore, the role of pathologists is essential and useful tools for immunohistochemistry diagnosis are needed. Polypeptide-GalNAc-transferases are emerging novel biomarkers related to cancer behavior and GalNAc-T13, correlated with aggressiveness in some tumors, is an interesting candidate. Few monoclonal antibodies reacting with native proteins, and not affected by fixation and paraffin embedding, have been reported. The aim of this work was to develop a useful monoclonal antibody anti-GalNAc-T13 and to assess its potential significance in breast cancer diagnosis. We evaluated 6 human breast cancer cell lines, 338 primary breast tumors and 48 metastatic lymph nodes and looked for clinical significance correlating GalNAc-T13 expression with patients’ clinical features and survival. We found high GalNAc-T13 expression in 43.8% of the cases and observed a significant higher expression in metastatic lymph nodes, correlating with worse overall survival. We hypothesized several possible molecular mechanisms and their implications. We conclude that GalNAc-T13 may be a novel biomarker in breast cancer, useful for routine pathological diagnosis. Elucidation of molecular mechanisms related to aggressiveness should contribute to understand the role of GalNAc-T13 in breast cancer biology.
format	article
author	Eugenia Fernandez Luis Ubillos Nabila Elgul María Florencia Festari Daniel Mazal Otto Pritsch Isabel Alonso Eduardo Osinaga Nora Berois
author_facet	Eugenia Fernandez Luis Ubillos Nabila Elgul María Florencia Festari Daniel Mazal Otto Pritsch Isabel Alonso Eduardo Osinaga Nora Berois
author_sort	Eugenia Fernandez
title	Polypeptide-GalNAc-Transferase-13 Shows Prognostic Impact in Breast Cancer
title_short	Polypeptide-GalNAc-Transferase-13 Shows Prognostic Impact in Breast Cancer
title_full	Polypeptide-GalNAc-Transferase-13 Shows Prognostic Impact in Breast Cancer
title_fullStr	Polypeptide-GalNAc-Transferase-13 Shows Prognostic Impact in Breast Cancer
title_full_unstemmed	Polypeptide-GalNAc-Transferase-13 Shows Prognostic Impact in Breast Cancer
title_sort	polypeptide-galnac-transferase-13 shows prognostic impact in breast cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/330d301d32ec460dad1dd19e0b6ffb40
work_keys_str_mv	AT eugeniafernandez polypeptidegalnactransferase13showsprognosticimpactinbreastcancer AT luisubillos polypeptidegalnactransferase13showsprognosticimpactinbreastcancer AT nabilaelgul polypeptidegalnactransferase13showsprognosticimpactinbreastcancer AT mariaflorenciafestari polypeptidegalnactransferase13showsprognosticimpactinbreastcancer AT danielmazal polypeptidegalnactransferase13showsprognosticimpactinbreastcancer AT ottopritsch polypeptidegalnactransferase13showsprognosticimpactinbreastcancer AT isabelalonso polypeptidegalnactransferase13showsprognosticimpactinbreastcancer AT eduardoosinaga polypeptidegalnactransferase13showsprognosticimpactinbreastcancer AT noraberois polypeptidegalnactransferase13showsprognosticimpactinbreastcancer
_version_	1718412768017645568

Polypeptide-GalNAc-Transferase-13 Shows Prognostic Impact in Breast Cancer

Ejemplares similares